NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes.
News provided by
Share this article
®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg). The NCCN ORP convened a Scientific Review Committee to review, evaluate, and select awardees and will provide oversight for the two-year studies—which will commence later in 2021. Research funding will be provided by a grant from Taiho Oncology, who will also supply the decitabine and cedazuridine tablet.